[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,726,228
  • Shares Outstanding, K 147,637
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 2,420 M
  • EBITDA $ 3,493 M
  • 60-Month Beta 0.19
  • Price/Sales 2.84
  • Price/Cash Flow 8.42
  • Price/Book 1.51

Options Overview Details

View History
  • Implied Volatility 31.94% (-1.91%)
  • Historical Volatility 35.84%
  • IV Percentile 20%
  • IV Rank 18.83%
  • IV High 50.85% on 10/16/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 1) 2.95 (1.56%)
  • Put/Call Vol Ratio 1.05
  • Today's Volume 413
  • Volume Avg (30-Day) 1,786
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 54,019
  • Open Int (30-Day) 53,339
  • Expected Range 186.50 to 192.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 35 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $3.36
  • Number of Estimates 21
  • High Estimate $4.40
  • Low Estimate $2.33
  • Prior Year $5.47
  • Growth Rate Est. (year over year) -38.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
179.15 +5.58%
on 04/27/26
205.97 -8.17%
on 05/13/26
+3.19 (+1.72%)
since 04/21/26
3-Month
168.64 +12.16%
on 04/06/26
205.97 -8.17%
on 05/13/26
-2.89 (-1.50%)
since 02/20/26
52-Week
121.05 +56.25%
on 07/21/25
205.97 -8.17%
on 05/13/26
+62.32 (+49.14%)
since 05/21/25

Most Recent Stories

More News
Are Wall Street Analysts Bullish on Biogen Stock?

Biogen has rallied the broader market over the past year, and analysts remain moderately optimistic about the stock’s prospects.

XLV : 148.22 (+0.74%)
$SPX : 7,445.22 (+0.16%)
BIIB : 189.83 (+1.08%)
BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud

Biogen revealed Phase 2 CELIA trial data that sent BIIB shares down approximately 6.4% in a single session.

BIIB : 189.83 (+1.08%)
BIIB ALERT: Levi & Korsinsky Investigates Biogen Inc. for Possible Securities Fraud Violations

New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Biogen Inc. ("Biogen Inc.") (NASDAQ:BIIB) concerning potential violations...

BIIB : 189.83 (+1.08%)
BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations

Biogen Phase 2 CELIA trial data sent shares down 6.4% after it was revealed that topline data missed its primary endpoint.

BIIB : 189.83 (+1.08%)
Biogen Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Biogen Inc. (BIIB)

Biogen shares dropped 6.4% after Phase 2 CELIA trial data revealed information absent from the Company's filings.

BIIB : 189.83 (+1.08%)
Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny - Contact Levi & Korsinsky for Details

New York, New York--(Newsfile Corp. - May 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Biogen Inc. ("Biogen Inc.") (NASDAQ: BIIB) concerning potential violations...

BIIB : 189.83 (+1.08%)
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push

Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company’s next phase of growth, Adam...

BIIB : 189.83 (+1.08%)
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

Robust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study 1 Pre-specified analyses of cognitive endpoints...

BIIB : 189.83 (+1.08%)
3 Healthcare Stocks We’re Skeptical Of

3 Healthcare Stocks We’re Skeptical Of

UHS : 162.25 (-1.26%)
TNDM : 15.70 (+4.39%)
BIIB : 189.83 (+1.08%)
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

TOKYO and CAMBRIDGE, Mass. , May 8, 2026 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period...

BIIB : 189.83 (+1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 199.01
2nd Resistance Point 196.19
1st Resistance Point 192.00
Last Price 189.83
1st Support Level 184.99
2nd Support Level 182.17
3rd Support Level 177.98

See More

52-Week High 205.97
Last Price 189.83
Fibonacci 61.8% 173.53
Fibonacci 50% 163.51
Fibonacci 38.2% 153.49
52-Week Low 121.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.